TABLE 5.

Susceptibilities of gram-negative bacteria isolated from skin and soft tissue specimens of hospitalized patients in four European countries, Canada, and the United States to antimicrobials^a

Organism	Antimicrobial agent	France		Germany		Italy		Spain		Canada		United States
		No. of isolates	% Susceptible	No. of isolates	% Susceptible	No. of isolates	% Susceptible	No. of isolates	% Susceptible	No. of isolates	% Susceptible	No. of isolates	% Susceptible
E. coli	Cefotaxime	4,460	99.5	2,827	99.4	638	92.6	2,964	96.1	868	96.3	1,626	96.9
	Ceftazidime	3,944	98.6	1,387	99.4	968	93.1	2,756	95.7	1,129	96.8	2,650	95.9
	Ceftriaxone	273	98.2	179	100	738	92.7	51	98.0	998	97.1	2,795	97.8
	Ciprofloxacin	3,759	92.8	2,485	92.8	1,025	82.1	3,084	77.1	1,373	91.6	3,004	90.6
	Gentamicin	4,459	94.9	2,771	96.1	1,022	88.2	3,079	86.1	1,492	92.8	3,712	93.4
	TMP-SMX	4,162	75.6	2,709	78.9	906	69.9	3,088	64.1	1,548	84.9	3,669	80.7
Klebsiella spp.	Cefotaxime	1,225	96.4	90	95.7	200	88.0	790	86.1	416	98.3	913	93.8
	Ceftazidime	1,151	95.3	437	97.3	287	82.6	752	85.5	589	97.8	1,485	90.7
	Ceftriaxone	83	88.0	54	100	216	86.6	NAb	NA	524	97.9	1,554	93.1
	Ciprofloxacin	1,088	94.5	764	92.5	303	90.4	825	94.9	676	93.9	1,667	90.2
	Gentamicin	1,227	97.2	895	97.4	302	91.1	822	87.5	722	97.9	2,024	94.1
	TMP-SMX	1,129	90.8	876	91.1	267	83.9	825	82.8	767	94.1	1,988	89.4
Citrobacter spp.	Cefotaxime	434	83.2	282	85.5	101	73.3	213	82.6	123	77.2	358	75.7
	Ceftazidime	403	79.7	158	71.5	144	67.4	198	81.8	146	77.4	563	74.3
	Ceftriaxone	NA	NA	NA	NA	112	69.6	NA	NA	131	71.8	561	77.7
	Ciprofloxacin	388	87.1	248	94.0	145	94.5	291	94.2	185	94.1	590	88.5
	Gentamicin	437	94.5	281	97.2	144	97.2	291	96.2	191	92.7	729	93.0
	TMP-SMX	396	89.9	271	96.3	130	95.4	291	92.1	196	89.8	717	89.4
Enterobacter spp.	Cefotaxime	1,486	71.1	494	74.7	282	64.2	630	80.2	408	72.8	195	70.8
	Ceftazidime	1,446	66.0	285	70.9	377	59.7	616	76.8	461	77.2	371	69.0
	Ceftriaxone	121	57.0	NA	NA	244	59.8	NA	NA	414	77.1	397	71.0
	Ciprofloxacin	1,386	76.9	409	91.9	379	80.0	938	94.4	595	93.6	420	95.2
	Gentamicin	1,491	93.1	493	97.8	380	85.5	938	98.2	634	98.0	489	96.1
	TMP-SMX	1,356	81.1	469	95.7	324	83.3	939	94.7	641	95.9	480	96.0
Proteus spp.	Cefotaxime	2,183	98.8	705	99.3	401	71.1	1,060	99.2	171	99.4	547	96.9
	Ceftazidime	1,963	98.8	357	98.9	505	85.0	988	98.9	249	97.6	898	98.7
	Ceftriaxone	95	99.0	95	96.8	360	75.6	NA	NA	214	99.1	1,048	96.0
	Ciprofloxacin	1,880	87.3	603	96.0	530	75.1	1,175	88.5	300	95.7	1,040	88.3
	Gentamicin	2,184	93.5	689	97.0	530	58.3	1,172	89.0	318	95.0	1,316	90.7
	TMP-SMX	1,894	81.3	659	82.9	459	54.0	1,173	66.5	332	87.7	1,296	84.6
P. aeruginosa	Amikacin	4,094	84.0	471	94.3	1,920	75.1	1,869	97.5	632	92.3	2,639	92.6
	Cefepime	3,726	71.7	580	87.8	1,227	67.7	1,915	75.3	108	80.6	2,449	80.0
	Cefotaxime	NA	NA	376	6.9	1,168	5.1	1,425	7.2	312	18.6	989	11.4
	Ceftazidime	4,090	83.8	864	89.7	2,106	61.2	2,034	77.6	1,548	85.2	3,662	79.3
	Ceftriaxone	NA	NA	NA	NA	1,305	8.4	NA	NA	606	14.2	1,852	13.2
	Ciprofloxacin	4,082	70.3	847	77.5	2,102	49.9	2,046	70.5	1,518	74.8	3,520	67.3
	Gentamicin	3,541	58.1	816	83.8	2,094	49.0	2,043	71.4	1,425	80.6	3,915	77.5
	Imipenem	4,096	83.6	844	84.6	1,931	77.2	1,929	81.0	1,159	87.8	3,393	83.4
	Piperacillin-tazobactam	3,835	83.1	775	93.9	1,161	77.3	1,846	84.5	929	92.4	2,863	88.7

^aSkin and soft tissue infection specimen sources were skin, skin ulcer, decubitis ulcer, subcutaneous biopsy, skin biopsy, abscess, soft tissue, surgical wound, subphrenic abscess, drainage pus, splenic abscess, renal abscess, perirectal abscess, liver abscess, pancreatic abscess, and intraabdominal abscess. Data are cumulative for 2000 to 2001.

^bNA, not available, <50 results were available.